bachem peptides: Supplier Overview & CDMO Standards
Disclaimer: All content on this site is an educational summary of public academic and industry research, compiled for informational reference only. It is not medical or laboratory advice. No treatment, health, or purchasing decisions should be made based solely on website content. This site does not sell peptides, does not link sellers, and does not endorse any vendor or any use of any compound.
What the public record shows
bachem peptides stands for something different from every other name in this cluster: regulated, audited peptide manufacturing. The Swiss group, founded in 1971 and headquartered in Bubendorf, Switzerland, is one of the world's largest peptide contract development and manufacturing organizations (CDMOs), listed on the SIX Swiss Exchange, with decades of peptide API production for approved pharmaceuticals. It supplies drug substances, not research-chemical vials — the institutional mirror image of the gray market this site documents.
The reason bachem anchors the tier system: its record includes exactly the things gray-market vendors cannot produce — GMP-compliant facilities, regulatory inspections, batch genealogy, pharmacopeial monographs, and audited quality systems. Where a storefront's COA is a self-attested PDF, a CDMO's batch record is a regulatory artifact embedded in approved-drug documentation chains.
Testing and documentation record
What a CDMO documentation set looks like: drug master files, validated analytical methods (the same LC-MS/HPLC chemistry described on the janoshik testing services page, but under validation protocols), stability programs, and impurity qualification per ICH guidelines. Peptide APIs from such suppliers feed approved medicines across metabolic, oncology and diagnostic applications — the tier where “peptide” stops being a research category and becomes a pharmaceutical supply chain.
For researchers, the comparison lesson is calibration, not shopping direction: bachem's standards define what “documented” means at the top of the market. When this cluster grades storefronts on COA granularity and batch traceability, the axes are the simplified, public-facing shadows of the CDMO disciplines described here.
Risk profile and category context
The tier contrast matters for scope, not for shaming: gray-market vendors and CDMOs serve different buyers with different obligations. An individual researcher cannot buy a kilogram of GMP peptide API any more than a pharmaceutical company can file a drug application built on unverified research vials. The two tiers coexist; only one of them is documented.
For the institutional reader, the vendor-qualification question for any peptide supplier — bachem or a competitor — reduces to the same checklist: accreditation scope, audit history, batch documentation depth, and regulatory references. ISO 17025 (testing) and GMP (manufacturing) are the floor standards; the comparison table below maps the tier differences against the gray market covered in the rest of this cluster.
How researchers verify this brand
Using this overview: (1) map any supplier to its tier by documentation type, not by claims; (2) for institutional qualification, request the audit trail: accreditations, inspection history, batch records, method validation packages; (3) compare the axes below to see exactly which guarantees exist only in the regulated tier; (4) for research-grade purchases, apply the cluster's five-field standard as always — the tiers are different products, not different prices.
The chemistry is identical across tiers — peptide bonds, HPLC, mass spectrometry (see the science pillar); what differs is documentation depth. That is the entire thesis of this site's tier system.
How to use the data on this page
Step 1 — extract the parameters. Extract: for any supplier, list documentation types (COA, DMF, audit report, validation package) and match to tier.
Step 2 — normalize before comparing. Normalize: a GMP batch record and a storefront COA are not comparable documents; never score them on the same axis without noting the tier difference.
Step 3 — grade the source. Grade: CDMO regulatory documentation grades Tier 1; gray-market self-attestation grades Tier 3-4.
Parameter comparison
Tier comparison: regulated CDMO supply vs the gray research market.
| Property | CDMO (e.g. bachem) | Gray-market storefront |
|---|---|---|
| Facilities | GMP-audited plants | Unaudited / undisclosed |
| Batch records | Full genealogy, drug master files | Self-attested lot COAs |
| Methods | Validated, pharmacopeial | Stated per COA, variable |
| Oversight | Regulatory inspections | None (research-use only) |
| Buyers | Pharma / institutions | Individual researchers |
Table: Tier comparison: regulated CDMO supply vs the gray research market. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
Where is precision peptides located?
We have no verified public documentation for a precision peptides facility location, and this site does not publish addresses it cannot source. Location claims about gray-market vendors should be treated as claims until tied to documentation — domain registration, payment processing and shipping origin frequently disagree, as gray-market analyses show. For suppliers whose locations are documented — like bachem (Bubendorf, Switzerland) — the record is stated plainly.
Does this site sell bachem products or any peptides?
No. simple peptides co is an independent research site: no sales, no storefront links, no affiliations with any supplier named in its pages.
References
- Public corporate disclosures of bachem group (founded 1971, Bubendorf, Switzerland; SIX-listed peptide CDMO) — Tier 1 regulatory/corporate record.
- ICH and GMP guidelines for peptide API manufacture; ISO 17025 laboratory standards.
- Pharmacopeial analytical method conventions (LC-MS, HPLC).